Literature DB >> 6809735

Pathways of acetoacetate's formation in liver and kidney.

P S Brady, R F Scofield, S Ohgaku, W C Schumann, G E Bartsch, J M Margolis, K Kumaran, A Horvat, S Mann, B R Landau.   

Abstract

Specifically 14C-labeled palmitic acids were perfused through livers and incubated with slices of kidneys from rats in diabetic ketosis. The distribution of 14C in the hydroxybutyric acid formed was determined. In liver, the ratio of incorporation of 14C from [13-14C]palmitic acid into carbon 1 to carbon 3 of the hydroxybutyric acid was the same as the ratio in carbon 2 to carbon 4 from [6-14C]palmitic acid. In kidney, the carbon 1-to-carbon 3 ratio was more than twice the carbon 2-to-carbon 4 ratio. In both tissues, 14C from [16-14C] palmitic acid was preferentially incorporated into carbon 4 compared to carbon 2 of the hydroxybutyric acid, but more so in liver than kidney. These results mean that in liver, the sole pathway of acetoacetate formation is via hydroxymethylglutaryl-CoA, while in kidney it is not. Rather in kidney, acetoacetyl-CoA is converted to acetoacetate to a large extent by direct deacylation, presumably via a transferase- and/or deacylase-catalyzed reaction. In liver, most of the palmitic acid utilized is converted to acetoacetate while in kidney it is not. We previously estimated that, as a minimum, 11% of the hydroxybutyric acid excreted by the rat in diabetic ketosis is formed without hydroxymethylglutaryl-CoA as an intermediate. The kidney appears to be the source of this hydroxybutyric acid if the pathways operative in these tissues in vitro are those that also operate in vivo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6809735

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  Labeled oxidation products from [1-14C], [U-14C] and [16-14C]-palmitate in hepatocytes and mitochondria.

Authors:  C Chatzidakis; D A Otto
Journal:  Lipids       Date:  1987-09       Impact factor: 1.880

2.  Hepatic and renal metabolism before and after portasystemic shunts in patients with cirrhosis.

Authors:  O E Owen; M A Mozzoli; F A Reichle; T H Kreulen; R S Owen; G Boden; M Polansky
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

3.  Determination of Krebs cycle metabolic carbon exchange in vivo and its use to estimate the individual contributions of gluconeogenesis and glycogenolysis to overall glucose output in man.

Authors:  A Consoli; F Kennedy; J Miles; J Gerich
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

4.  Genomic and Metabolomic Profile Associated to Clustering of Cardio-Metabolic Risk Factors.

Authors:  Vannina G Marrachelli; Pilar Rentero; María L Mansego; Jose Manuel Morales; Inma Galan; Mercedes Pardo-Tendero; Fernando Martinez; Juan Carlos Martin-Escudero; Laisa Briongos; Felipe Javier Chaves; Josep Redon; Daniel Monleon
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.